Epoprostenol and Lamivudine share 2 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.200 means 20% of the combined target set is bound by both compounds. The IDF-weighted score of 0.136 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Epoprostenol and Lamivudine have in common?
Epoprostenol and Lamivudine share 2 molecular targets with a Jaccard similarity of 20%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Epoprostenol and Lamivudine be combined?
Epoprostenol and Lamivudine share 2 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Epoprostenol or Lamivudine?
Both Epoprostenol and Lamivudine have substantial PubMed research. View their individual profiles for full evidence scores.